SANTA MONICA, Calif., March 9 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com/ ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it believes the executive order signed today by President Obama eliminating restrictions on Federal funding of stem cell research is a significant move forward for the entire stem cell sector.
"Scientists are confident that stem cell research will lead to fundamental improvements in the treatment of heart disease, diabetes, Parkinson's disease and other of our most difficult to treat illnesses," said Matthew Schissler, Cord Blood America Founder and CEO.
"Stem cells are believed capable of becoming any tissue in the body, which could lead to treatments for illnesses currently impossible to cure," Mr. Schissler said. "The more positive news about stem cells and their medical uses, the more we believe parents and grandparents will understand the importance of umbilical cord blood stem cell storage, done at the time of birth by Cord Blood America.
"Storing stem cells is the inventory business model needed for future therapies. As the stem cell research companies drive their respective trials forward, we'll be ready with the inventory as therapies become commercialized. Without the inventory in storage, a great therapy can bypass a patient in need," Mr. Schissler said.
"A perfect example of why storage is so important was chronicled by The Official Journal of the American Academy of Pediatrics, which released the report, 'First Report of Autologous Cord Blood Transplantation in the Treatment of a Child with Leukemia,' in Pediatrics 2007; 119: 296-300 on January 3, 2007. Cord Blood America's subsidiary, CorCell, was fortunate enough to have stored these stem cells which led to this ultimate successful result," Cord Blood America's founder said.
Learn more about this transplant at http://www.corcell.com/about/press_010307.html
About Cord Blood America
Cord Blood America (BULLETIN BOARD: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com
